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a b s t r a c t
We describe a young girl with dilated cardiomyopathy, long QT syndrome, and possible energy deﬁciency. Two
major sequence changes were identiﬁed by whole exome sequencing (WES) and mitochondrial DNA analysis
that were interpreted as potentially causative. Changes were identiﬁed in the KCNH2 gene and mitochondrial
tRNA for cysteine. A variation was also seen in MYPBC3. Since the launch of WES as a clinically available technology in 2010, there has been concern regarding the identiﬁcation of variants unrelated to the patient's phenotype.
However, in cases where targeted sequencing fails to explain the clinical presentation, the underlying etiology
could be more complex than anticipated. In this situation, the extensive reach of this tool helped explain both
her phenotype and family history.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Whole exome sequencing (WES) is a powerful tool that can be utilized
for the identiﬁcation of pathogenic mutations. However it can also identify variants unrelated to phenotype. Here, we present a patient identiﬁed
to have multiple mutations by WES that more effectively describe their
complex phenotype than a single change.
Our patient initially came to attention for dilated cardiomyopathy
(DCM) but also had a history of sensorineural hearing loss. Her clinical
course was complicated as she had required extracorporeal membrane
oxygenation (ECMO) on several occasions without a clear precipitating
event. Her cardiac and family history prompted concern that there may
be more than one cause for her ﬁndings. However extensive previous
testing had been non-diagnostic, so WES was performed during a particularly serious and protracted hospital admission. Initial WES interpretation implicated genes associated with DCM, long QT syndrome
(LQTS) in addition to multiple variants. Mitochondrial DNA sequencing
identiﬁed a transfer RNA variant.

Typically, DCM can present with heart failure, cardiac arrhythmias or
sudden cardiac death in an otherwise seemingly healthy individual. It
has an estimated prevalence of 36 per 100,000 individuals and 25–30%
of those cases are familial [1–3]. Inheritance patterns may be autosomal
dominant, autosomal recessive, X-linked or mitochondrial. Massive parallel sequencing technologies have allowed the identiﬁcation of the responsible gene in up to 40% of cases of familial DCM, making possible the
screening of asymptomatic at-risk individuals [4–6].
LQTS is another leading cause of sudden cardiac death in children
and its prevalence has been estimated to be as high as 1 in 2000 [7].
Gene sequencing panels currently available can identify mutations in
75% of patients with congenital LQTS [4].
Although the prevalence of congenital LQTS in families with DCM
has not been studied, both conditions are most commonly inherited in
an autosomal dominant manner. The contribution of a change in mitochondrial transfer RNA and LQTS in the context of a DCM variant of unknown signiﬁcance could have potentiated a fatal scenario.
2. Case presentation
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A 4 year old girl with sensorineural hearing loss and speech delay
initially presented to the emergency room due to breathing difﬁculty.
Physical exam revealed a non-dysmorphic appearance with evidence
of cardiovascular compromise and generalized hypotonia. Dilated eye
exam was normal. Family history was signiﬁcant for an older sister
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with speech delay and hearing loss who passed suddenly at age
2 years. The autopsy interpreted her death secondary to myocarditis, presumed to be of viral etiology. Both parents and two younger sisters were
reportedly healthy although none had been evaluated formally for
hearing or cardiac concerns. Two older paternal half-sisters were also reportedly healthy.
Upon admission, an echocardiogram revealed dilated cardiomyopathy
(DCM). Endomyocardial biopsy showed no signs of myocarditis, negative
viral DNA/RNA (adenovirus, CMV, EBV, enterovirus, parvovirus) and mild
to moderate subendothelial ﬁbrosis. Skeletal muscle biopsy was normal
and included histochemical stains for mitochondrial oxidative phosphorylation defects (cytochrome C oxidase and succinate dehydrogenase),

and analysis for ragged red ﬁbers. Biochemical analyses to include plasma
amino acids, urine organic acids, an acylcarnitine proﬁle, and total and
free carnitine were also normal.
During this initial presentation and hospitalization, the patient
required extracorporeal membrane oxygenation (ECMO) with a left ventricular assist device (LVAD) and was evaluated for heart transplantation,
but her cardiac function recovered prior to the anticipated surgery
(Fig. 1). During the next four years, she was hospitalized ﬁve more
times with acute heart failure and decompensation. Additional molecular
genetic testing completed during these hospitalizations included chromosomal oligoarray (GeneDx, 2011), dilated cardiomyopathy sequencing
panel (GeneDx, 2011, 27 genes), connexin 26 and connexin 30, Otoscope

Fig. 1. 1–3: Initial presentation in congestive heart failure. (2) and (3) were obtained prior to placement on ECMO after rapidly worsening cardiac function. (1) Mildly dilated left atrium
and ventricle. (2) parasternal short axis image showing minimal motion of the interventricular septum and excursion of the posterior wall, suggesting severely decreased left ventricular
function. The calculated shortening fraction (SF) was 10% (normal range 28–40%). (3) Apical 4 chamber view showing generalized dilatation with thin left ventricular walls, consistent
with dilated cardiomyopathy (DCM). The left ventricle also shows mild hypertrabeculation of the posterior wall which can represent non-compaction of the left ventricle. There is a thrombus in the right atrium (shown with the arrow). Images 4 and 5 were obtained between hospitalizations and show complete echocardiographic resolution of her failed systolic function.
(4) Parasternal short axis view showing a thicker ventricular septum and posterior walls more consistent with non-compaction/hypertrophic cardiomyopathy (HCM) when compared
with (2). Note the normal excursion of both walls. SF was 37%. (5) Apical 4 chamber view showing normal systolic function and signiﬁcant hypertrabeculation.

Table 1
Results of WES clinical testing (Baylor, Molecular Diagnostics Laboratory) in the initial proband.
Gene

Protein

Function

Variants
MYPN

Myopalladin

TTN

Titin

TTN

Titin

TTN

Titin

TTN

Titin

TTN

Titin

COG6

Component of
the oligomeric
Golgi complex 6
GIPC PDZ
domain
containing
family
Mediator
complex subunit
23
Laminin

GIPC3

MED23

LAMA2
UPF3B

UPF3 regulator
of nonsense
transcripts
homolog B

Isoform

Location Variant
Variant
(amino acid) (protein)

Chr11:47367777

NM_000256 Exon 11

c. 1071CNT

p.Arg358X

Chr7:150647150

NM_172058 Exon 9

c.2503del C

p.Leu835fs

m.5814TNC

Genbank accession
numbers

Parent
of
origin

Pathogenicity Predicted
phenotype

Polyphen/SiFT Polymorphism
or ESP5400
status

ENSG00000134571 Mother Likely
pathogenic
ENSG0000055118
Father Likely
pathogenic

HCM/DCM

NA/NA

Not reported

LQTS2

NA/NA

Not reported

HGNC:7477

Mother Pathogenic

Mitochondrial
myopathy
MELAS
asymptomatic

Mother VUS

DCM/HCM

rs147287437

ESP5400

Interacts with nebullete in
cardiac muscle and nebulin
in skeletal muscle in Z-lines
Major component in
striated muscle
Major component in
striated muscle
Major component in
striated muscle
Major component in
striated muscle
Major component in
striated muscle
Component of the conserve
oligomeric Golgi complex

Chr10:69934085

NM_032578 Exon 11

c.2236ANG

p.Thr746Ala

Chr2:179455631

c.53117CNT

p.Pro177706Leu ENSG00000155657 Father

VUS

c.57388CNT

p.Arg19130Cys

ENSG00000155657 Father

VUS

Chr2:179603991

NM_133378 Exon
253
NM_133378 Exon
260
NM_003319 Exon 45

c.12880ANC

p.Asn4294HIs

ENSG00000155657 Father

VUS

Chr2:179585257

NM_133378 Exon 77

c.19500CNG

p.Asn6500Lys

ENSG00000155657 Father

VUS

Chr2:
179612873
Chr13:40235007

NM_133379 Exon 46

c.14254ANC

p.Ser4752Arg

ENSG00000155657 Mother VUS

NM_020751 Exon 3

c.358ANG

p.Ser120Gly

ENSG00000133103

VUS

CM, MD,
myopathy
CM, MD,
myopathy
CM, MD,
myopathy
CM, MD,
myopathy
CM, MD,
myopathy
CDG III

Role in hair bundle survival

Chr19:3590081

NM_133261 Exon 6

c.832GNA

p.Glu278Lys

ENSG00000179855 Novel

VUS

Deafness AR15

Novel

Role in identiﬁcation of
enhancer sites in DNA for
transcription
Component of basement
membrane
Regulates post-splicing
multiprotein complex

Chr6:131908846

NM_004830 Exon 29

c.4080GNT

p.Val1360Val

ENSG00000112282

VUS

rs138742804

Chr6:129759787

NM_000426 Intronic

c.5969-4GNA

ENSG00000196569 Novel

VUS

Intellectual
disability (AR
18)
MD (Merosin)

ENSG00000125351 Father

VUS

Intellectual
disability
(X-linked 14)

rs143538947

Chr2:179449188

ChrX:118971901 NM_080632 Exon 10

c.1121GNA

p.Arg374His

ESP5400
ESP5400
ESP5400
rs146504870
rs139313781
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Mutations per initial clinical reports
MYBPC3 Myosin binding
Binds myosin to modulate
protein C
contraction
Potassium ﬂow during
KCNH2
Membrane
repolarization
potassium
channel
MT-TC
tRNA Cys
Mitochondrial cysteine
transport

Position

Novel

49

50

M.J. Guillen Sacoto et al. / Molecular Genetics and Metabolism Reports 3 (2015) 47–54

panel (University of Iowa 2012, 66 genes), were all non-diagnostic. The
contents of each of these studies are listed in Appendix A.
Her average length of hospital stay was 41 days and after prolonged
periods of cardiac and nutritional support she would fully recover to
cardiac baseline. One prolonged hospitalization with apparent end
organ failure required over three months of ECMO therapy. The chronicity and severity of these episodes were unusual particularly with the
family history of sudden death and sensorineural hearing loss, and
more aggressive molecular analysis was pursued.
3. Molecular diagnostics
Whole exome sequencing (WES) inclusive of mitochondrial DNA testing targeting 162 nuclear and 37 mitochondrial genes (Baylor College of
Medicine/MitomeNGSSM) was requested and revealed a maternally
inherited “pathogenic” mutation in MYBPC3 and a likely pathogenic mutation in KCNH2 that was paternally inherited. Pathogenicity was determined by Mercury 1.0 (Baylor) [8]. All reported mutations and variants
are listed in Table 1 and Appendix A. The MYBPC3 mutation was later
reclassiﬁed as a variant of unknown signiﬁcance (VUS).
Our patient also had an apparently homoplasmic mutation affecting
the mitochondrial transfer RNA Cysteine (tRNA Cys) that was interpreted
as pathogenic (Table 1 and Appendix A).

Neither one of the parents nor other older relatives had a known
history of cardiac disease (Pedigree in Appendix B). The family was
informed of the testing results and extensive genetic counseling was provided. The patient eventually died at 8 years of age after decompensation
following a sudden illness. One of the patient's younger sisters was subsequently diagnosed with sensorineural hearing loss and developmental
delay. Serial echocardiogram and EKG analyses have been normal, and
she has never been hospitalized. Recent molecular testing showed that
she has the same change in mitochondrial tRNA Cys in addition to the
MYBPC3 variant. Testing of her deceased older sister was not able to be
completed.
4. Discussion
The combination of hearing loss and cardiomyopathy, in our patient
and her deceased sister, suggested an underlying genetic etiology.
However the initially available tools for genetic testing failed to provide
a diagnosis until massive parallel sequencing of the entire exome became
available.
Common causes of dilated cardiomyopathy in children include myocarditis, inﬁltrative disease and drugs. Approximately 50% of cases are
considered idiopathic of which 20–50% are thought to be familial, depending on the screening methods used [3,9]. Our patient was found

Fig. 2. The 3 pathogenic mutations and their interaction in the heart are depicted. Loss of function mutations in KCNH2 and a membrane potassium channel are associated with long QT
syndrome type 2 (LQTS2). In LQTS2 loud noises can trigger torsades de pointes, ultimately leading to syncope, seizures or sudden cardiac death. Cardiac myosin-binding protein C, encoded
by MYBPC3, binds myosin and when phosphorylated mediates contraction. The mytochondrial transfer RNA-cysteine (tRNACys) localizes within the mitochondria and abnormal synthesis
of mitochondrial proteins and/or oxidative stress imbalances have been associated with DCM [20]. We postulate that abnormalities in cardiac myosin-binding protein C were responsible
for the dilated cardiomyopathy present in our patient and the mitochondrial dysfunction secondary to the mutation in the tRNACys had an additive effect on the severity of the phenotype.
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to have a likely pathogenic mutation in the MYBPC3 gene, usually associated with hypertrophic cardiomyopathy (40%), but also reported in 4%
of patients with familial or idiopathic dilated cardiomyopathy [10]. It
was not reported abnormal in the initial cardiomyopathy panel ordered
for this patient although included.
Interestingly, WES also revealed a mutation in KCNH2 associated
with LQTS type 2 [11]. Although, we have no evidence of long QT in
our patient, individuals with mutations in KCNH2 are at increased risk
of sudden cardiac death, even in the absence of electrocardiographic abnormalities [12,13].
Mitochondrial genome sequencing was ordered concurrently to consider an explanation to the patient's hearing loss, initial presentation of
hypotonia, and severe recurrent episodes of heart failure. Mitochondrial
disease can be secondary to alterations in mitochondrial proteins, which
in turn can be encoded by nuclear or mtDNA [14]. Many mitochondrial
mutations also affect the tRNA genes. Pathogenic mutations have been
reported in 1 in 200 live births, however the prevalence of mitochondrial
disorders is about 1 in 10,000 [15]. In general, mitochondrial disease refers
to disorders of the respiratory chain, which tend to effect in organs with
high energy demand, like the myocardium, and mitochondrial cardiomyopathy is a well-recognized entity [16,17]. Not surprisingly, mitochondrial
dysfunction has been associated with cardiomyopathy [18,19] and mutations in the mitochondrial genome affecting tRNA have been identiﬁed in
individuals with DCM [20,21].
Mitochondrial DNA is solely maternally inherited in most instances
[22], and in this family, as two of four children have been identiﬁed
with homoplasmic mutations, the laboratory interpretation (personal
discussion with Baylor Miraca Genetics Laboratories) is that there is a
probability of maternal homoplasmy as well. The mutation in the tRNA
Cys, found in our patients has been reported in other patients with encephalomyopathy and mitochondrial myopathy, Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-like episodes (MELAS), hearing loss
as well as asymptomatic family members [23–25]. As SNHL was present
in both our patient and her sister who did not have the long QT mutation, we feel that the mitochondrial tRNA Cys change is the underlying
etiology.
Additionally, we feel that the mitochondrial mutation may have
contributed to or even potentiated the clinical presentation of cardiomyopathy and the seemingly complete remission after prolonged
and intensive cardiac support (Fig. 1). There are reports of a child
with both long QT and hypertrophic cardiomyopathy mutations as
well as a child with same tRNA Cys mutation who hypertrophic
cardiomyopathy and mitochondrial myopathy [26,27], but none of
a patient or family similar to ours.
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WES also allows the determination of the parent of origin in the case
of inherited mutations. All family members carrying either mutation
have been recommended to undergo routine clinical screening along
with genetic testing. Screening offered to family members included
echocardiography and EKGs.
The exact cause of the sudden cardiac death in the older sister is unclear. It is quite possible that she also carried the same mutations or variants in mitochondrial tRNA Cys, MYBPC3, KCNH2, or a combination of
more than one. Post-mortem genetic testing could have potential beneﬁt for the family [26], though was not possible in this case. Nevertheless,
information regarding both the mechanisms and related risks to all surviving family members may prove to be invaluable for their health.

5. Conclusions
As we continue to accumulate information on variants found by whole
exome sequencing, it is likely that we will be able to better classify them as
benign or pathogenic. While mutations in any one of these three genes
can convey pathogenicity in a variable manner, it is clear that in combination, initial cardiac stress also became a risk for both rhythm disturbances
and dilated cardiomyopathy, ultimately leading to functional compromise. The identiﬁcation of the two individual gene mutations via clinical
testing may have provided an initial clue, but not the full physiologic phenotype for this child's cardiac risks and intermingled pathology (Fig. 2).
Multiple episodes of full cardiac support via ECMO allowed the myocardium to rest but the underlying genetic risks to metabolic stress may have
ultimately led to this child's passing. We also feel that it is important to
consider the possible contribution of the sequence variation in MYBPC3,
as may also have potentiated pathogenicity under the unique circumstance of mitochondrial compromise and arrhythmia.
This case demonstrates that multiple underlying genetic mechanisms should be considered in extraordinary clinical presentations.
We offer that multiple genetic mutations and/or variants of unclear
signiﬁcance may be acting synergistically to compound phenotype.
Thoughtful identiﬁcation can have a profound effect upon both the
patient's care and counseling to other family members regarding their
own health risks.
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Appendix A

Gene test

Gene Dx Microarray 2011

GeneDX dilated cardiomyopathy
panel 2011

Otoscope

Saint Francis

Whole exome

Mitochondrial
DNA

Results

No deletions duplication

No mutations identiﬁed

No mutations
identiﬁed

No mutations
identiﬁed

Mutations and variations within

Mutations

Genes

180,000 oligonucleotide probes

LMNA
LDB3/ZASP
TTNT2
DES
SGCD
ACTC1
PLN
MYH7
TPM1
TNNI3
TAZ

ATCG1
CCDC50
CDH23
CLDN14
CLRN1
COCH
COL11A2
CRYM
DRNA5
DIAPH1
DSPP

Cx26/GJB2
CX30/GJB6

Per publshed protocol Reid et al.

MT-TC (m.5814TNC)

Mutations
KCNH2 (c.2503delC)
Variations
MYBPC3 (c.1071CNT)
MYPN (c.2236ANG)
TTN (c.53117CNT)
TTN (c. 57388CNT)
TTN (c. 12880ANC)
TTN (c.19500CNG)
(continued on next page)
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Appendix
A (continued)
(continued)
Gene test

Gene Dx Microarray 2011

GeneDX dilated cardiomyopathy
panel 2011

Otoscope

Saint Francis

Whole exome

Mitochondrial
DNA

Results

No deletions duplication

No mutations identiﬁed

No mutations
identiﬁed

No mutations
identiﬁed

Mutations and variations within

Mutations

TTR
MYBPC3
LAMP2
MTTK
MTTL1
MTTL2
MTTQ
MTTH
MTTD
MTTI
MTTV
MTTS1
MTTS2
MTND1
MTND5
MTND6

ESPN
ESSRB
EYA4
GIPC3
CX26/GJB2
GJB3
CX30/GJB6
GPR96
GPSM2
GRHL2
GRXCR1
HGF
ILDR1
KCNQ4
LHFPL5
LOXHD1
LRTOMT
MARVELD2
miR-96
miR-182
miR-183
MTRNR1
MTTS1
MYH14
MYH9
MYO1A
MYO15A
MYO3A
MYO6
MYO7A
OTOA
OTOF
PCDH15
PJVK
POU3F4
POU4F3
PRPS1
PTPRQ
RDX
SLC17A3
SLC26A4
SLC26A5
STRC
TECTA
TJP2
TMC1
TMIE
TMPRSS3
TPRN
TRIOBP
USH1C
USH1G
USH2A
WFS1
WHRN

TTN (c. 14254ANC)
COG6 (c. 358ANG)
GIPC3 (c. 832GNA)
MED23 (c.4080GNT)
LAMA2 (c. 5969-4GNA)
UPF3B (c. 1121GNA)
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